Home
GLUE
GLUE News

Latest Monte Rosa Therapeutics Inc. (GLUE) News on December 22, 2024

MT Newswires

3 days ago

Wells Fargo Downgrades Monte Rosa Therapeutics to Equalweight From Overweight, Cuts Price Target to $11 From $14

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

GlobeNewswire

9 days ago

Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors

MT Newswires

11 days ago

Monte Rosa Therapeutics Preclinical Trial of Potential Breast Cancer Therapy Shows Less Toxicity, Tumor Regression

MT Newswires

11 days ago

Monte Rosa Closes Global License Agreement With Novartis

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

GlobeNewswire

11 days ago

Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

GlobeNewswire

11 days ago

Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study

TipRanks

16 days ago

Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

GlobeNewswire

17 days ago

Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors

Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?

Zacks

20 days ago

Wall Street Analysts See a 64.09% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

GlobeNewswire

a month ago

Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet

Zacks

a month ago

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

GlobeNewswire

a month ago

Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference

Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE),

Simply Wall St.

a month ago

Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE),

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates

Zacks

a month ago

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates

Associated Press Finance

a month ago

Monte Rosa Therapeutics: Q3 Earnings Snapshot

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a month ago

Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice

Zacks

2 months ago

Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice

Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade

Zacks

2 months ago

Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade

Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler

TipRanks

2 months ago

Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler

Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis

GuruFocus.com

2 months ago

Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis

Monte Rosa Almost Doubles — Up 94% — On A Massive Deal With Novartis

Investor's Business Daily

2 months ago

Monte Rosa Almost Doubles — Up 94% — On A Massive Deal With Novartis

MT Newswires

2 months ago

Top Midday Gainers

This Biotech Stock Has Doubled Its Value Today—Here's Why

Investopedia

2 months ago

This Biotech Stock Has Doubled Its Value Today—Here's Why

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis

Investor's Business Daily

2 months ago

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis

MT Newswires

2 months ago

Wedbush Adjusts Price Target on Monte Rosa Therapeutics to $15 From $11, Maintains Outperform Rating

Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs

Reuters

2 months ago

Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs

Why Is Monte Rosa Therapeutics Stock Surging On Monday?

Benzinga

2 months ago

Why Is Monte Rosa Therapeutics Stock Surging On Monday?

MT Newswires

2 months ago

Monte Rosa Therapeutics Enters Global License Deal With Novartis; Shares Jump Pre-Bell

Monte Rosa joins with Novartis in ‘molecular glue’ drug deal

BioPharma Dive

2 months ago

Monte Rosa joins with Novartis in ‘molecular glue’ drug deal

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

GlobeNewswire

2 months ago

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

GlobeNewswire

2 months ago

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors

Argus Research

3 months ago

Daily – Vickers Top Buyers & Sellers for 09/25/2024

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

4 months ago

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth

Simply Wall St.

4 months ago

Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth

MT Newswires

4 months ago

Monte Rosa Therapeutics Doses First Participants in MRT-6160 Autoimmune Study

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

GlobeNewswire

4 months ago

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

Zacks

4 months ago

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

Associated Press Finance

4 months ago

Monte Rosa Therapeutics: Q2 Earnings Snapshot

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

4 months ago

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

GlobeNewswire

5 months ago

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

GlobeNewswire

6 months ago

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

GlobeNewswire

6 months ago

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Business Wire

6 months ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

GlobeNewswire

6 months ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23

GlobeNewswire

6 months ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Simply Wall St.

6 months ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May

Reuters

6 months ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

AFP

6 months ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

GlobeNewswire

6 months ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Enduring role of 'treasuring the past' hailed

PR Newswire

6 months ago

Enduring role of 'treasuring the past' hailed

Institutional investors own a significant stake of 40% in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

Simply Wall St.

7 months ago

Institutional investors own a significant stake of 40% in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)

MT Newswires

7 months ago

Monte Rosa Therapeutics Names Three Insiders to Leadership Team

Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

7 months ago

Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference

Monte Rosa Therapeutics Announces Leadership Team Promotions

GlobeNewswire

7 months ago

Monte Rosa Therapeutics Announces Leadership Team Promotions

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

GlobeNewswire

7 months ago

Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease

MT Newswires

7 months ago

Monte Rosa Therapeutics Prices $100 Million Public Offering

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

GlobeNewswire

7 months ago

Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire

7 months ago

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GuruFocus.com

7 months ago

Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview

Associated Press Finance

7 months ago

Monte Rosa Therapeutics: Q1 Earnings Snapshot

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

7 months ago

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

GlobeNewswire

8 months ago

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

MT Newswires

8 months ago

UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating

Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why

Zacks

8 months ago

Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why

Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?

Zacks

9 months ago

Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?

Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

9 months ago

Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why

Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know

Zacks

9 months ago

Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know

GuruFocus.com

9 months ago

Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results

Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

Simply Wall St.

9 months ago

Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

Associated Press Finance

9 months ago

Monte Rosa Therapeutics: Q4 Earnings Snapshot

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire

9 months ago

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

GlobeNewswire

9 months ago

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

Unitil Increases Common Stock Dividend

GlobeNewswire

a year ago

Unitil Increases Common Stock Dividend

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Carrols Restaurant Group (TAST) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Zacks

a year ago

Carrols Restaurant Group (TAST) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Sierra Bancorp (BSRR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

a year ago

Sierra Bancorp (BSRR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Despite Fast-paced Momentum, Carrols Restaurant (TAST) Is Still a Bargain Stock

Zacks

a year ago

Despite Fast-paced Momentum, Carrols Restaurant (TAST) Is Still a Bargain Stock

Southside Bancshares, Inc. (NASDAQ:SBSI) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Southside Bancshares, Inc. (NASDAQ:SBSI) Q4 2023 Earnings Call Transcript

Oppenheimer Holdings Full Year 2023 Earnings: EPS: US$2.81 (vs US$2.77 in FY 2022)

Simply Wall St.

a year ago

Oppenheimer Holdings Full Year 2023 Earnings: EPS: US$2.81 (vs US$2.77 in FY 2022)

West Bancorporation Full Year 2023 Earnings: EPS Misses Expectations

Simply Wall St.

a year ago

West Bancorporation Full Year 2023 Earnings: EPS Misses Expectations

Compared to Estimates, Midland States Bancorp (MSBI) Q4 Earnings: A Look at Key Metrics

Zacks

a year ago

Compared to Estimates, Midland States Bancorp (MSBI) Q4 Earnings: A Look at Key Metrics

Midland States Bancorp (MSBI) Q4 Earnings and Revenues Beat Estimates

Zacks

a year ago

Midland States Bancorp (MSBI) Q4 Earnings and Revenues Beat Estimates

Midland States Bancorp Inc (MSBI) Reports Mixed Q4 Earnings Amid Economic Headwinds

GuruFocus.com

a year ago

Midland States Bancorp Inc (MSBI) Reports Mixed Q4 Earnings Amid Economic Headwinds

First Bank Announces Fourth Quarter 2023 Net Income of $8.4 Million and Full Year Net Income of $20.9 Million

GlobeNewswire

a year ago

First Bank Announces Fourth Quarter 2023 Net Income of $8.4 Million and Full Year Net Income of $20.9 Million

Eaton achieves Mansfield Rule certification: Legal Department Edition 3.0

Business Wire

a year ago

Eaton achieves Mansfield Rule certification: Legal Department Edition 3.0

Associated Press Finance

a year ago

Bar Harbor: Q4 Earnings Snapshot

Bar Harbor Bankshares Reports Fourth Quarter 2023 Results

ACCESSWIRE

a year ago

Bar Harbor Bankshares Reports Fourth Quarter 2023 Results

Zacks Market Edge Highlights: MODG, BALY, FNKO, IIPR and DFIN

Zacks

a year ago

Zacks Market Edge Highlights: MODG, BALY, FNKO, IIPR and DFIN

The Manitowoc Company, Inc. (MTW) Increases Yet Falls Behind Market: What Investors Need to Know

Zacks

a year ago

The Manitowoc Company, Inc. (MTW) Increases Yet Falls Behind Market: What Investors Need to Know

Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting

PR Newswire

a year ago

Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting

Business Wire

a year ago

Manitowoc Board of Directors Elects Ryan M. Gwillim as New Director

Bar Harbor Bankshares Declares Quarterly Cash Dividend

ACCESSWIRE

a year ago

Bar Harbor Bankshares Declares Quarterly Cash Dividend

Reuters

a year ago

GRAPHIC-As price parity beckons, substitution from palladium to platinum to wane

3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street

Motley Fool

a year ago

3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street

Zacks.com featured highlights AZZ, Heartland Financial, CEMEX, Noah and ASE Technology

Zacks

a year ago

Zacks.com featured highlights AZZ, Heartland Financial, CEMEX, Noah and ASE Technology

Billionaire Steve Cohen Aggressively Bought These 12 Stocks Recently

Insider Monkey

a year ago

Billionaire Steve Cohen Aggressively Bought These 12 Stocks Recently

The Manitowoc Company, Inc. (MTW) Stock Dips While Market Gains: Key Facts

Zacks

a year ago

The Manitowoc Company, Inc. (MTW) Stock Dips While Market Gains: Key Facts

MainStay MacKay DefinedTerm Municipal Opportunities Fund's Dividend Analysis

GuruFocus.com

a year ago

MainStay MacKay DefinedTerm Municipal Opportunities Fund's Dividend Analysis

At the 2024 Golden Globes, Diamonds Were Forever

WWD

a year ago

At the 2024 Golden Globes, Diamonds Were Forever

Gladstone Capital Announces Monthly Cash Distributions for January, February and March 2024 and Conference Call Date

ACCESSWIRE

a year ago

Gladstone Capital Announces Monthly Cash Distributions for January, February and March 2024 and Conference Call Date

Share on Social Networks: